US EditionForitinib Gains Momentum in China for ALK-positive NSCLC - ILCN.org (ILCN/WCLC)
Summary by ILCN.org (ILCN/WCLC)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Foritinib Gains Momentum in China for ALK-positive NSCLC - ILCN.org (ILCN/WCLC)
There is a growing demand for targeted therapies in patients with ROS1-rearranged non-small cell lung cancer (NSCLC); However, some of the currently approved treatments have been associated with adverse side effects, including inadequate intracranial activity or central nervous system (CNS)-related toxicities.1 China’s National Medical Products Administration (NMPA) has recently accepted a marketing authorization application for foritinib, a nov…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
